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The Role of Monitoring Interpretive Rates, Concordance
Between Cytotechnologist and Pathologist Interpretations
Before Sign-Out, and Turnaround Time in Gynecologic
Cytology Quality Assurance
Findings From the College of American Pathologists Gynecologic Cytopathology
Quality Consensus Conference Working Group 1
Karen M. Clary, MD; Diane D. Davey, MD; Sonya Naryshkin, MD; R. Marshall Austin, MD, PhD; Nicole Thomas, CT(ASCP);
Beth Anne Chmara, CT(ASCP); Chiara Sugrue, MBA, MS, SCT(ASCP); Joseph Tworek, MD
 Context.—The College of American Pathologists (CAP)
conducted a national survey of gynecologic cytology
quality assurance (QA) practices. Experts in gynecologic
cytology were asked to join 5 working groups that studied
the survey data on different aspects of QA. Evaluating the
survey data and follow-up questions online, together with
a review of pertinent literature, the working groups
developed a series of preliminary statements on good
laboratory practices in cytology QA. These were presented
at a consensus conference and electronic voting occurred.
Objective.—To evaluate a set of QA monitors in
gynecologic cytology. Working group 1 evaluated (1)
monitoring interpretive rate categories for Papanicolaou
tests (Pap tests), (2) concordance of cytotechnologist and
pathologist interpretations before sign-out, and (3) turn-
around time for Pap tests.
Data Sources.—The statements are based on a survey of
gynecologic cytology QA practice patterns and of opinions
from working group members and consensus conference
attendees.
Conclusions.—The outcomes of this process demon-
strate the current state of practice patterns in gynecologic
cytology QA. Monitoring interpretive rates for all Bethesda
System categories is potentially useful, and it is most useful
to monitor interpretive rates for cytotechnologists individ-
ually and in comparison to the entire laboratory. Labora-
tories need to determine what level of discrepancy
between cytotechnologist and pathologist interpretations
of Pap tests is important to track. Laboratories should
consider formalizing procedures and policies to adjudicate
such discrepant interpretations. Turnaround time should
be monitored in gynecologic cytology, but individual
laboratories should determine how to measure and use
turnaround time internally.
(Arch Pathol Lab Med. 2013;137:164–174; doi: 10.5858/
arpa.2012-0120-CC)
Monitoring interpretive rate categories for Papanicolaoutests (Pap tests), concordance of cytotechnologist and
pathologist interpretations before sign-out, and turnaround
time are 3 categories of monitors that may be useful for
quality assurance in gynecologic cytology. These quality
assurance measures were evaluated as part of a larger
project by the College of American Pathologists (CAP) that
surveyed a wide range of quality assurance monitors in
gynecologic cytology. The monitoring of interpretive rates
is mandated by the Clinical Laboratory Improvement
Amendments of 1988 (CLIA ’88) and by accrediting
agencies, including the CAP. Most frequently, such rates
are monitored for the entire laboratory and for cytotech-
nologists, and less frequently for pathologists. Determining
what rates should be monitored, who should be moni-
tored, how frequently, and how such monitoring should
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occur within the laboratory were issues addressed in this
study.
Cytotechnologists and pathologists work in tandem to
identify potentially precancerous and cancerous cells on Pap
tests. Disagreements may arise between the cytotechnolo-
gist and pathologist as to the presence of abnormal cells, or
the degree of abnormality identified on the Pap test. The
manner in which these disagreements are handled will
potentially impact patient care. Tracking such disagree-
ments between cytotechnologists and pathologists may be
used as a quality metric. Objectives for quality assurance
guidelines are to determine if and how concordance/
discordance of cytotechnologist and pathologist interpreta-
tions should be used as a metric. Other questions are how
and when to adjudicate discrepancies between cytotechnol-
ogists and pathologists, and what types of cases should be
shown to a third party before sign-out of the Pap test by the
pathologist.
Turnaround time (TAT) for Pap tests is a readily quantified
measure in the cytology laboratory. However, the effective-
ness of TAT as a quality metric is debatable. Turnaround
time may relate more to customer satisfaction or to
laboratory staffing than to laboratory quality. Monitoring
TAT may have a negative impact if its use causes undue
pressure on cytotechnologists, resulting in rushing Pap test
screening. If and how monitoring TAT should be part of a
quality assurance plan in the cytology laboratory is at issue.
METHODS
The CAP, with support from the Centers for Disease Control and
Prevention (CDC), conducted a national survey of quality
assurance practices in gynecologic cytology. This Web-based
survey was developed by the 3 senior authors of the CAP project
with input from national organizations (CAP Cytopathology
Resource Committee, the American Society of Cytopathology, the
American Society for Cytotechnology, and the American Society of
Clinical Pathology), and CDC colleagues. The survey was
distributed to all laboratories that participate in gynecologic
cytology proficiency testing in the United States, and more than
540 survey responses were received. For details of the complete
process of this study, including the development of the survey,
enhanced Web-based input, and culmination in a consensus
conference, see the introductory article.1 In short, expert cytopa-
thologists and cytotechnologists were recruited to become part of 5
working groups that studied the survey data on different aspects of
quality assurance. These working groups added follow-up ques-
tions to the survey, which were available online and elicited
additional opinions. Evaluating the data and follow-up questions,
together with a review of the literature, the working groups
developed a series of preliminary statements on good laboratory
practices in cytology quality assurance and presented these at a
consensus conference in Rosemont, Illinois, on June 4, 2011.
Participants in the conference included working group members,
representatives from national cytopathology and cytotechnology
organizations, Centers for Medicare and Medicaid Services (CMS),
the CDC, and individuals who accepted invitations after complet-
ing the written survey. Representatives from the working groups
presented their draft statements to the audience participants who
voted electronically on the issues. Some statements received a clear
consensus from the audience, some had clearly no consensus, and
for others, consensus was questionable. The stratified consensus
responses were categorized as ‘‘agreement’’: 70% to 79%;
‘‘moderately strong agreement’’: 80% to 89%; ‘‘strong agreement’’:
90% to 98%; and ‘‘nearly complete agreement’’: 99% to 100%. The
voting resulted in a number of consensus good laboratory practice
statements. Limitations of the process include the small number of
participants in the consensus conference, and the basis largely on
expert opinion, rather than on evidenced-based practices.
RESULTS
Monitoring Interpretive Rates
The monitoring of interpretive rates is common practice
among the laboratories surveyed, although which rates are
monitored and the frequency of monitoring varies (Tables 1
and 2). Some interpretive rates are either mandated by CLIA
regulations and/or required as a component of laboratory
certification by deemed organizations, especially the CAP.
Theoretically, some interpretive rates, such as the percent-
age of cancer, are population-specific indices that are not
expected to vary over time unless there is a shift in the
demographics of the patient population served. And, as
different laboratories serve populations of women with
different demographics, interpretative rates would be
expected to vary among laboratories. For example, CAP
benchmarking data from 2006 showed that the rate of low-
grade squamous intraepithelial lesion (LSIL) on liquid-
based Pap tests varied among laboratories from a low of
1.1% at the fifth percentile to more than 7% at the 95th
percentile. Rates for high-grade squamous intraepithelial
lesion (HSIL) varied more than 20-fold from 0.1% to 2%.2
That being said, cervicovaginal cytology does have a
subjective component to interpretations, and thus interpre-
tive rates could vary as a reflection of thresholds for specific
interpretations, such as between atypical squamous cells of
undetermined significance (ASCUS) and LSIL, for example.
In this regard, the monitoring of interpretive rates might be
useful for intralaboratory monitoring of consistency, which
cytotechnologists and pathologists use in applying inter-
pretative criteria. Published scientific data concerning the
usefulness of the application of the monitoring of specific
diagnostic rates to an effective quality assurance program,
however, is quite scant, and thus this area is wide open for
future research exploration. That which might seem logical
or intuitive on the surface may not always bear out after
subjection to scientific scrutiny. For example, the limited
published data concerning the correlation of overall
abnormal pickup rates and false-negative fraction3 showed
no correlation. Findings such as this are important to
consider when making choices as to which metrics to use
and for which purposes.
Survey Results.—Another example would be that of
regular monitoring of categories of abnormalities subject to
poor interobserver and intraobserver variability, such as
ASCUS. Such monitoring makes sense in regard to an
individual laboratory’s reproducibility of results, and the
subsequent trust that clinicians may put in such reports.
Indeed, the monitoring of ASCUS was reported by 83.9% of
528 laboratories (Table 1), the highest rate for any of the
diagnostic categories, indicating a great degree of consensus
that ASCUS is an important diagnostic rate to monitor.
ASCUS is also one of the categories that is most subject to
‘‘diagnostic drift’’ and variability among both pathologists
and cytotechnologists. Because the ASCUS to squamous
intraepithelial lesion ratio (ASCUS:SIL ratio) has much less
variability than the ASCUS rate, this monitor is more useful
for interlaboratory comparisons, such as in benchmarking.4
Indeed, in our written survey, the ASCUS:SIL ratio was the
only interpretive rate opined to be very useful by more than
half of respondents (53.5 %) (Table 3). A study correlating
cytotechnologists’ ASCUS:SIL ratios with sensitivity5
showed that the mean screening sensitivity for cytotech-
nologists with ASCUS:SIL ratios less than 1.5 was
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significantly less than that for cytotechnologists whose
ASCUS:SIL ratio was more than 3.0. The authors also
suggested that an ASCUS:SIL ratio less than 1.5 for a
cytotechnologist might be useful as a surrogate marker for
inadequate screening sensitivity. Note that this study
compared ASCUS:SIL ratios of individual cytotechnologists
before final interpretation of cases by pathologists, and thus
higher ratios are expected. Indeed, the 2006 CAP bench-
marking data2 showed that the average laboratory ASCUS:
SIL ratio was about 1.5. However, too much emphasis on a
low ASCUS:SIL ratio in a laboratory could potentially have a
negative impact on laboratory sensitivity. A recent clinical
trial showed that several laboratories with ASCUS:SIL ratios
of 1.5 or less had less than 50% adjusted screening
sensitivity for cervical intraepithelial neoplasia grade 2þ.6
Therefore, benchmarking data without data correlating it to
quality outcomes can be deceptively reassuring.
Interestingly, 41.9% of written survey respondents re-
ported that other undesignated diagnostic rates, not listed
on the survey, were useful to them in monitoring quality
(Table 3). This obviously requires more study.
The most common interval for monitoring of diagnostic
rates was monthly (Table 2). As diagnostic rates for entities
other than ASCUS tend to be rather stable over time unless
there is a shift in demographics, the monthly frequency of
monitoring probably reflects a logistic convenience, as many
laboratories collect the raw data for calculating error rates
on a monthly basis. For rates with expected fluctuations,
such as ASCUS or ASCUS:SIL, monthly monitoring might
make more sense. However, such frequent monitoring may
pose a problem for small laboratories with extremely small
volumes, such as 500 or less cases per year, as their rates
may fluctuate widely just by statistical chance. Also,
comparing their rates to published benchmarks may also
be misleading for the same reason. Some laboratories use a
rolling 12 months of data collection, which can be analyzed
monthly, quarterly, or at some other interval, based upon
the suitability to individual laboratories. This is an area that
needs more research.
Follow-up Questions Posted on Internet Site.—The
detailed comments from the follow-up online questions
were interesting. Only 56% of 87 respondents reported ever
seeing a shift in an actively monitored diagnostic rate
laboratory-wide. A similar percentage reported ever seeing
a shift in an actively monitored individual diagnostic rate,
but the reasons attributed to the changes were different. The
most common factors (mentioned in 25% of the comments
each) attributed to the shift were a change in technique/
methodology, such as adding imaging or switching to a
different liquid-based method and personnel receiving
feedback about recently missed cases, review of diagnostic
criteria, and others. For shifts in individual diagnostic rates,
the common factor attributed was the individual receiving
feedback or participating in open discussion, supporting the
intuitive importance of providing feedback to individuals.
Common but less frequently cited reasons were a change in
personnel (pathologists or cytotechnologists) and imple-
mentation of human papillomavirus (HPV) testing or review
of HPV results.
When asked why participants found that monitoring
ASCUS was helpful, most alluded to the fact that ASCUS is
the clinical decision point, and an indicator of the threshold
of abnormality. Participants felt that monitoring ASCUS
rates prevents overcalling and undercalling and helps to
keep interpretations within the laboratory uniform. How-
ever, the follow-up online questions revealed that of 87
respondents, 71% and 68% reported that ASCUS rates
varied greatly both among cytotechnologists and patholo-
gists, respectively. This seems to challenge the impression
that merely monitoring the ASCUS rates would necessarily
Table 1. Actively Monitored Diagnostic Rates (N ¼ 528)
Diagnostic Rate
Laboratory Cytotechnologist Pathologist
Frequency Percentage Frequency Percentage Frequency Percentage
None 9 1.7 17 3.2 56 10.6
NILM 407 77.1 374 70.8 169 32.0
Unsat 443 83.9 380 72.0 182 34.5
LSIL 437 82.8 398 75.4 208 39.4
HSIL 435 82.4 399 75.6 207 39.2
SCC 383 72.5 337 63.8 180 34.1
Other malignancies 355 67.2 311 58.9 161 30.5
ASCUS 443 83.9 404 76.5 215 40.7
ASC-H 398 75.4 359 68.0 194 36.7
AGC 399 75.6 361 68.4 192 36.4
ASCUS:SIL ratio 424 80.3 324 61.4 198 37.5
NILM:SIL ratio 96 18.2 82 15.5 46 8.7
Other 90 17.0 75 14.2 46 8.7
Abbreviations: AGC, atypical glandular cells; ASC-H, atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion; ASCUS,
atypical squamous cells of undetermined significance; ASCUS:SIL ratio, the ratio of cases with an interpretation of atypical squamous cells of
undetermined significance to cases with squamous intraepithelial lesions; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade
squamous intraepithelial lesion; NILM, negative for intraepithelial lesion or malignancy; NILM:SIL ratio, the ratio of cases with an interpretation of
negative for intraepithelial lesion or malignancy to cases with squamous intraepithelial lesions; SCC, squamous cell carcinoma; Unsat,
unsatisfactory.
Table 2. Monitoring Frequency
How Frequently Are the Diagnostic Rates Monitored?
Frequency Percentage
Daily 9 1.8
Weekly 3 0.6
Monthly 333 64.8
Bimonthly 4 0.8
Quarterly 62 12.1
Semiannually 65 12.6
Annually 32 6.2
Other 6 1.2
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produce uniformity. One respondent mentioned that
cytotechnologists who miss ASCUS also tend to miss HSIL,
an observation that is supported by the literature.3
When asked which interpretive rates were felt to not be
useful, most comments included relatively rare but signif-
icant interpretations such as atypical glandular cells, atypical
squamous cells, cannot exclude high-grade squamous
intraepithelial lesion (ASC-H), and cancer. This issue was
discussed in detail at the conference, and the suggestion was
made to combine these categories into a monitor that could
be followed even in low-volume laboratories. However,
43.5% of attendees at the consensus conference felt that this
was not useful. Only future research will clarify this newly
identified controversy.
Another category felt to be problematic, and one
documented now to lead to many unnecessary procedures,
was normal endometrial cells in women older than 40 years.
This was also a topic of discussion at the conference.
Scientific data show that the only women with normal-
appearing endometrial cells who may require endometrial
sampling or ultrasound assessment are those who are
postmenopausal or having clinically abnormal bleeding.7
From the follow-up online questions, most reporting
laboratories (95%) monitor the total abnormal rate. Eighty-
two percent monitor both laboratory and individual rates.
More than half of the respondents (58%) felt that
cytotechnologists and pathologists should have access to
their diagnostic rates. Such feedback was felt to be helpful
because it provided ‘‘peer pressure’’ to outliers, making
counseling easier when needed; helped people know how
they were doing in relation to others in the laboratory and to
CAP benchmarks; improved education and sharing of cases;
helped to refine skills and cytologic criteria; and helped with
accuracy and managing of diagnostic thresholds.
Fifty-nine percent of online respondents felt that each
person’s individual interpretive rates should be shared
confidentially with him or her. Several commented that it
was helpful to openly publish/display interpretive rates
within the laboratory, but that people should not be
individually identifiable. A few commented that the sharing
of interpretive rates could actually be a negative, depending
upon how they were used, for example, as a basis for merit
raises. While there are correlations between some rates and
performance, such as the correlation between ASCUS:SIL
ratios and sensitivity cited above, such correlations are not
absolute; therefore, it is important to use more than 1
metric. This once again brings up the importance of tying
benchmarks to clinically significant metrics such as error
rates or sensitivities for significant lesions.
Consensus Good Laboratory Practice Statements and
Comments.—Table 4 lists the good laboratory practice
statements generated from the survey, the Internet follow-
up questions, and opinions of the authors for monitoring
interpretive rates in gynecologic cytology. These statements
were voted on at the consensus conference, and in cases
where there was no clear initial consensus, the statements
were revised and voted on again.
Concordance of Cytotechnologist
and Pathologist Interpretations
Tracking discrepancies between cytotechnologists and
pathologists is incorporated into the evaluation of individual
performance as mandated by CLIA. However, the methods
for monitoring and analyzing discrepancies are not speci-
fied. The CAP checklist requires documentation of each
individual’s diagnostic discrepancies and corrective actions
taken (CYP.07660). The CAP checklist also requires
comparison of individual cytotechnologist interpretation to
the final diagnosis in gynecologic specimens signed out as
abnormal, as part of the 6-month workload assessment
(CYP 0.08575). Most laboratories incorporate some evalu-
ation of discrepancy analysis as part of the every-6-month
workload review, and this has been advocated as a possible
quality metric.8–10 Establishing a baseline level of discrep-
ancies is important so that trends can be analyzed.
Individual discrepancy rates can be compared to the
laboratory rate, and individual rates can be tracked over
time. Laboratories also need to determine what level of
discrepancy is important to track and whether upgraded or
downgraded interpretations, or both, need to be monitored.
Laboratories should also consider formalizing procedures
and policies to adjudicate discrepant interpretations of Pap
tests between cytotechnologists and pathologists before
sign-out of the Pap test. Adjudication of discrepancies may
be challenging in laboratories with 1 pathologist and
cytotechnologist or in laboratories with only a pathologist.
Survey Results.—From the survey, greater than 73% of
laboratories actively monitor the rates at which a pathologist
upgrades a cytotechnologist’s diagnosis at the time of initial
Table 3. Usefulness of Diagnostic Rates in Monitoring Quality
Diagnostic Rate N Average Rank Very Useful 5, % 4, % 3, % 2, % Not Useful 1, %
NILM 439 3.6 33.3 21.6 24.1 11.8 9.1
Unsat 492 4.0 44.3 23.8 20.3 7.1 4.5
LSIL 490 4.0 41.8 26.9 22.9 5.7 2.7
HSIL 490 4.1 46.5 24.1 22.2 4.5 2.7
SCC 432 3.7 36.6 21.8 23.4 10.9 7.4
Other malignancy 409 3.6 35.7 20.3 24.9 10.3 8.8
ASCUS 492 4.2 51.0 23.8 18.1 5.3 1.8
ASC-H 459 4.0 44.2 24.4 21.4 6.5 3.5
AGC 451 3.8 33.3 28.8 23.9 8.9 5.1
ASCUS:SIL ratio 465 4.2 53.5 23.0 16.1 5.2 2.2
NILM-SIL ratio 132 3.5 33.3 18.9 23.5 11.4 12.9
Other 86 3.5 41.9 11.6 17.4 12.8 16.3
Abbreviations: AGC, atypical glandular cells; ASC-H, atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion; ASCUS,
atypical squamous cells of undetermined significance; ASCUS:SIL ratio, the ratio of cases with an interpretation of atypical squamous cells of
undetermined significance to cases with squamous intraepithelial lesions; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade
squamous intraepithelial lesion; NILM, negative for intraepithelial lesion or malignancy; NILM:SIL ratio, the ratio of cases with an interpretation of
negative for intraepithelial lesion or malignancy to cases with squamous intraepithelial lesions; SCC, squamous cell carcinoma; Unsat,
unsatisfactory. Rankings based on a scale of 1 to 5: not useful to very useful.
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sign-out, and greater than 62% of laboratories actively
monitor the rates at which a pathologist downgrades a
cytotechnologist’s diagnosis at the time of initial sign-out
(Table 5). The most critical upgrades monitored are from
negative for intraepithelial lesion or malignancy (NILM) to
either LSIL or to HSIL or greater, monitored respectively by
97.9% and 96.6% of the 381 laboratories that responded to
this survey question (Table 6). Upgrades from NILM to
ASCUS and to ASC-H are also frequently monitored by
74.8% and 81.9% of laboratories, respectively, as are
upgrades from ASCUS to HSIL, monitored by 83.2% of
laboratories. Monitoring upgrades from LSIL to HSIL and
ASC-H to HSIL was not as frequent, with only 65.9% and
57.0% of laboratories, respectively, following these rates.
The most frequent and most important downgrades
monitored by laboratories are from HSIL to NILM and
LSIL to NILM, each monitored by more than 94% of the 320
laboratories that responded to this question in the survey
(Table 7). Monitoring of downgrades from either ASC-H or
ASCUS to NILM is followed respectively by 80.6% and
72.5% of laboratories, and monitoring downgrades of HSIL
to either LSIL or to ASC-H is followed respectively by
64.4% and 60.6% of laboratories.
In adjudicating discrepancies between cytotechnologists’
and pathologists’ diagnoses, only 49.5% of laboratories have
a written policy specifying the process to resolve 2-grade
discrepancies, and only 25.2% have such a written policy in
cases of 1-grade discrepancies (Table 8). For 2-grade
discrepancies, the Pap test in question is frequently shown
by the pathologist to a second person before sign-out:
32.2% to the original cytotechnologist, 24.7% to another
pathologist, and 4.5% to another cytotechnologist. In only
33.7% of laboratories that responded did the pathologist
diagnosis stand without further action. By contrast, in the
case of 1-grade discrepancies, such as from LSIL to ASCUS,
most laboratories (68.5%) responded that the pathologist’s
diagnosis stands and only 27.6% responded that the case
was shown to a second person.
Follow-up Questions Posted on Internet Site.—Seven
additional questions were posted on a Web site in an
attempt to supplement the written survey questions. The
number of responses, ranging from 62 to 87, was low when
compared to the number of responders to the written
survey. From the responses, most pathologists (60%) seek
additional review of particular cases before downgrading a
cytotechnologist diagnosis (Table 9). The most frequent
cases that elicit second review are HSIL (78%), atypical
glandular cells (54%), and ASC-H (41%). Similarly, 37 of 61
cytotechnologists indicated that they seek additional review
before forwarding a case to a pathologist (Table 10). The
most frequent case shown by a cytotechnologist is a Pap test
interpreted as atypical glandular cells.
Forty-nine percent of pathologists indicated that they did
not routinely confirm an abnormal Pap test result by
showing it to another individual before sign-out (Table
Table 4. Consensus Good Laboratory Practice
Statements: Monitoring Interpretive Rates
1. Monitoring of interpretive rates for all Bethesda System
categories is potentially useful, as each Bethesda System
category is clinically relevant.
Do you agree with the consensus statement?
Yes: 94.3%
No: 5.7%
Should standard categories of interpretive rates be
monitored in all laboratories?
Yes: 85.1%
No: 6.3%
Should each individual laboratory choose which
interpretive rates to monitor?
Yes: 20.7%
No: 79.3%
2. It is most useful to monitor interpretive rates for
cytotechnologists individually and in comparison for
the entire laboratory.
Do you agree with the consensus statement?
Yes: 100%
3. It is currently unclear whether or not monitoring
interpretive rates for individual pathologists beyond
laboratory rates as a whole is useful.
Is monitoring interpretive rates of individual pathologists
useful to you?
Yes: 85.7%
No: 12.9%
Other: 1.4%
Is this an area that should be explored?
Yes: 90.5%
No: 3.2%
Other: 6.4%
4. Consider monitoring combined interpretive rates of
‘‘dangerous abnormals,’’ defined as cancer, suggestive
of cancer, HSIL, AGC, and ASC-H.
Do you think that using the combined category
‘‘dangerous abnormals’’ could be useful?
Yes, in low-volume/low-prevalence laboratories
only: 15.9%
Yes, in any laboratory: 34.8%
No: 43.5%
Don’t know: 5.8%
5. Monthly monitoring of interpretive rates may be
useful, if possible.
Is monthly monitoring:
Too frequent: 43.1%
Not frequent enough: 1.7%
Just right: 55.2%
5a. Revised statement: Regular monitoring of interpretive
rates may be useful and the individual laboratory should
determine the frequency of monitoring.
Do you agree?
Yes: 98.2%
No: 1.9%
6. Providing feedback of interpretive rates is important.
Should individual interpretive statistics be provided to
cytotechnologists and pathologists as feedback?
Yes, regularly: 88%
No, not at all: 1%
Only as part of scheduled employee reviews: 11%
Abbreviations: ACG, atypical glandular cells; ASC-H, atypical squa-
mous cells, cannot exclude high-grade squamous intraepithelial lesion;
HSIL, high-grade squamous intraepithelial lesion.
Table 5. Monitoring Change in Diagnosis
Frequency Percentage
The rates at which a pathologist upgrades a
cytotechnologist’s diagnosis at the time of
initial sign-out are actively monitored
per cytotechnologist:
Yes 376 73.3
No 137 26.7
The rates at which a pathologist downgrades
a cytotechnologist’s diagnosis at the time
of initial sign-out are actively monitored
per cytotechnologist:
Yes 312 62.5
No 187 37.5
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11). Of those pathologists that did confirm a diagnosis, this
was most frequently done at the discretion of the
pathologist and not for any specific interpretive category.
Frequently, Pap tests not interpreted as abnormal or reactive
are routinely reviewed by pathologists before sign-out
(Table 12). The most frequent Pap test in this category is
one containing herpes, shown by 81% of responders.
Unsatisfactory Pap tests and those with benign endometrial
cells follow those with herpes at 59% and 44%, respectively.
Written responses were solicited in the ‘‘other’’ category,
chosen by 29%. Many of these comments indicated that
endometrial cells identified in women either older than 40
years or older than 50 years, or the presence of Actinomyces,
were Pap tests that were frequently shown: (45% and 35%,
respectively).
Consensus Good Laboratory Practice Statements and
Comments.—Table 13 lists the good laboratory practices
generated by data from the written survey, the Internet
discussion site, and opinion of the authors for monitoring
concordance of cytotechnologist and pathologist interpre-
tations. These were voted on at the consensus conference
and in cases where there was no clear consensus, the
statements were reworded and resubmitted for voting.
As shown in Table 13, statement 1a, while there was
strong support to actively monitor upgrades of cytotech-
nologist interpretations, particularly of NILM to SILþ, by
pathologists, there was not clear consensus on which other
cytotechnologist interpretations should also be monitored.
The statement was revised and resubmitted.
Cytotechnologists are responsible for screening slides for
potential abnormalities. The rate at which interpretations
are upgraded was deemed to be an important quality
monitor by 79.7% of conference participants (Table 13,
statement 1b). However, there was no consensus as to the
definition of a significant discrepancy. Some laboratories
may choose to monitor any case upgraded from negative to
abnormal (ASCUSþ) plus upgrades from ASCUS or LSIL to
HSIL. Other laboratories may prefer to define upgraded
discrepancies more narrowly with normal to SILþ counted.
At the very least, upgrades of NILM to SILþ should be
considered as a monitor.
As shown in Table 13, statement 2, there was less
consensus as to whether downgraded interpretations should
be monitored. Some laboratories only monitored significant
downgrades, while other laboratories had broader defini-
tions. Pathologists are responsible for making the final
determination on abnormal cases, based not only on cellular
features but also clinical history and management implica-
tions. There is an expectation that many specimens
interpreted as potentially atypical by cytotechnologists will
be downgraded to negative by pathologists, and similarly,
there will be some cases in which a minor downgrade is
made because there is uncertainty as to the nature of an
abnormality. An example is a case downgraded from HSIL
to ASC-H when there is uncertainty, in order to prevent
potential overtreatment. In the written survey sent to
laboratories, many participants agreed that only significant
downgrades should be monitored. For example, 96.3% of
laboratories monitor downgrades of HSIL to negative,
whereas only 60.6% monitor downgrades from HSIL to
ASC-H.
Laboratories may address significant discrepancies in
interpretations between cytotechnologists and pathologists
in a variety of ways. Often the pathologist uses individual
discretion in determining which types of cases should be
adjudicated by a third person. In the written survey relating
to 2-step discrepancies, 33.7% of respondents stated that
the pathologist’s diagnosis stands without further action,
while most either reviewed the case with the cytotechnol-
ogist (32.2%) or consulted a second pathologist (24.7%). At
the conference, 62.5% strongly agreed that discrepancies of
2 degrees or more should be showed to a third person when
possible, and 29.2% agreed with reservations. Since clear
consensus was not obtained on which diagnostic categories
may benefit from review by a third person (Table 13,
statement 3a), the question was restated and resubmitted
Table 6. Upgrade Rates Monitored for Cytotechnologists (N ¼ 381)
Cytotechnologist Diagnosis
Pathologist Diagnosis
ASCUS ASC-H LSIL HSIL or Greater
Frequency Percentage Freq Percentage Freq Percentage Freq Percentage
NILM 285 74.8 312 81.9 373 97.9 368 96.6
ASCUS . . . . . . 179 47.0 216 56.7 317 83.2
LSIL . . . . . . 169 44.4 . . . . . . 251 65.9
ASC-H . . . . . . . . . . . . . . . . . . 217 57.0
Abbreviations: ASC-H, atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion; ASCUS, atypical squamous cells of
undetermined significance; Freq, frequency; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion;
NILM, negative for intraepithelial lesion or malignancy.
Table 7. Downgrade Rates Monitored for Cytotechnologists (N ¼ 320)
Cytotechnologist Diagnosis
Pathologist Diagnosis
NILM ASCUS ASC-H LSIL
Freq Percentage Freq Percentage Freq Percentage Freq Percentage
ASCUS 232 72.5 . . . . . . . . . . . . . . . . . .
ASC-H 258 80.6 158 49.4 . . . . . . . . . . . .
LSIL 302 94.4 189 59.1 . . . . . . . . . . . .
HSIL or greater 308 96.3 274 85.6 194 60.6 206 64.4
Abbreviations: ASC-H, atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion; ASCUS, atypical squamous cells of
undetermined significance; Freq, frequency; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion;
NILM, negative for intraepithelial lesion or malignancy.
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for a vote (statement 3b). Examples of cases meeting these
criteria would be upgrades from NILM to HSIL or
downgrades of cases from HSILþ to negative. Small
laboratories with only a single cytotechnologist and
pathologist have challenges in adjudicating discrepancies.
Some mechanisms for addressing discrepancies in small
laboratories include reviewing the case at a multiheaded
microscope, correlating the interpretation with later biop-
sies, and sending select cases out of the laboratory for
outside consultation. Obtaining HPV testing in certain
situations may be a possibility, but this has to be tempered
by the fact that there is a small false-negative rate of HPV
testing in HSIL and cancer cases.11,12 Furthermore, HPV
testing should be requested in consultation with the
clinician after discussion of possible pitfalls. Regardless of
how individual laboratories may handle discrepancies,
73.7% of consensus conference participants agreed that
laboratories should have policies about which categories of
discrepancies should be reviewed by a third individual
before sign-out. These policies will clarify expectations for
both cytotechnologists and pathologists and provide more
uniform handling of specimens, which may impact signif-
icantly on patient care. Policies dealing with 1-grade
discrepancies, such as from HSIL to ASC-H, are not as
critical as policies handling a 2-grade discrepancy such as
from HSIL to NILM. In the former case, there is no or
minimal change in patient management, while in the latter,
patient management will be different.
Certain types of high-risk specimens may especially
benefit from review by a third person; examples are atypical
glandular cells and those results, such as HSIL, that will
impact on the patient’s receiving colposcopy and biopsy.
Glandular lesions are problematic and are not infrequently
the cause of litigation. The voting at the consensus
conference reflects the awareness of difficulties in detecting
glandular lesions. Only 27.7% thought it unnecessary to
show a premalignant or malignant glandular lesion to a
third person, whereas 39.4% thought this was not needed
Table 9. For Pathologists, Are There Particular Cases
for Which You Seek Additional Review
Before Downgrading a Cytotechnologist Diagnosis?
Frequency Percentage
Yes 37 60
No 18 29
Unsure 7 11
Total 62 100
If Yes, for Which of the Following Diagnoses?
(Check All That Apply)
ASCUS 10 27
ASC-H 15 41
LSIL 7 19
HSIL 29 78
AGC 20 54
Abbreviations: AGC, atypical glandular cells of undetermined signif-
icance; ASC-H, atypical squamous cells, cannot exclude high-grade
squamous intraepithelial lesion; ASCUS, atypical squamous cells of
undetermined significance; HSIL, high-grade squamous intraepithelial
lesion; LSIL, low-grade squamous intraepithelial lesion.
Table 8. Additional Monitoring Characteristics
Frequency Percentage
In cases of a 2-grade or greater discrepant diagnosis between a pathologist and a cytotechnologist, how is the discrepancy most
commonly resolved?
The pathologist’s diagnosis stands without further action 172 33.7
By reviewing the Papanicolaou test with original cytotechnologist 164 32.2
Discrepancies are shown to a second pathologist 126 24.7
Other 24 4.7
Discrepancies are shown to a second cytotechnologist 23 4.5
By HPV testing 1 0.2
There is a written laboratory policy specifying the process for resolution of a 2-grade discrepancy:
Yes 252 49.5
No 257 50.5
In cases of a 1-grade or greater discrepant diagnosis between a pathologist and a cytotechnologist, how is the discrepancy most
commonly resolved?
The pathologist’s diagnosis stands without further action 350 68.5
By reviewing the Papanicolaou test with original cytotechnologist 94 18.4
Discrepancies are shown to a second pathologist 37 7.2
Other 18 3.5
Discrepancies are shown to a second cytotechnologist 10 2.0
By HPV testing 2 0.4
There is a written laboratory policy specifying the process for resolution of a 1-grade discrepancy:
Yes 129 25.2
No 383 74.8
Abbreviation: HPV, human papillomavirus.
Table 10. For Cytotechnologists, Are There Particular
Cases for Which You Seek Additional Review
Before Forwarding a Case on to a Pathologist?
Frequency Percentage
Yes 37 61
No 22 36
Unsure 2 3
Total 61 100
If Yes, for Which of the Following Cases?
(Check All That Apply)
ASCUS 16 46
ASC-H 15 43
LSIL 2 6
HSIL 9 26
AGC 20 57
Abbreviations: AGC, atypical glandular cells of undetermined signif-
icance; ASC-H, atypical squamous cells, cannot exclude high-grade
squamous intraepithelial lesion; ASCUS, atypical squamous cells of
undetermined significance; HSIL, high-grade squamous intraepithelial
lesion; LSIL, low-grade squamous intraepithelial lesion.
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for similarly severe squamous lesions (Table 13, statements
4 and 5).
Laboratories should have policies as to which cases
benefit from review by a second person (cytotechnologist
or pathologist), even if not required by CLIA. These may
include unsatisfactory, endometrial cells in women older
than 40 years, glandular cells in women post hysterectomy,
and herpes. CLIA requires that all reactive and potentially
abnormal cases be reviewed and confirmed by a pathologist.
However there is no requirement that certain Bethesda
categories be confirmed by a second individual. Some of
these types of specimens have important clinical manage-
ment implications. Examples include unsatisfactory speci-
mens, endometrial cells, and certain types of organisms
including herpes simplex virus (Table 13, statement 6a).
Greater than 90% of consensus conference participants
agreed that laboratories should have policies as to which
cases benefit from such review (Table 13, statement 6b).
Specimens designated as ‘‘unsatisfactory’’ generally require
early repeat according to American Society for Colposcopy
and Cervical Pathology management guidelines.13 Addi-
tional review helps to promote intralaboratory reproduc-
ibility in application of adequacy criteria. Furthermore,
patients who have received chemotherapy or radiation
therapy may have lower-cellularity specimens, and there are
no data to suggest a minimum numeric threshold; thus, the
pathologist may evaluate clinical history and exercise clinical
judgment in certain cases designated by the cytotechnolo-
gist as unsatisfactory.13 Endometrial sampling is recom-
mended for postmenopausal women with benign-
appearing endometrial cells, while women age 40 years or
older who are still having menstrual cycles and are
asymptomatic can return to routine screening.14 In addition,
differentiating atypical glandular cells from shed endome-
trial cells is challenging, and such cases benefit from
additional review.
Turnaround Time
Turnaround time has been historically associated with
causing pressure on cytotechnologists to increase produc-
tivity at the expense of quality.15 With the implementation of
CLIA ’88, however, strict regulations have limited the
number of slides cytotechnologists are allowed to screen per
day and individual workload limits are assessed biannually.
Given these quality measures, during the last decade the
concept of TAT has evolved to become a readily quantifiable
measure in the cytology laboratory and to have an impact
on quality.16 A timely reporting of results translates into
timeliness of patient care. However, it may be argued that
gynecologic cytology is a screening test, which decreases the
sense of urgency for the results.
Turnaround time is generally defined as the time a
specimen is accessioned in the laboratory to the time the
report is signed out or finalized. However, there is variability
among laboratories in defining when the TAT cycle starts
and when it ends.
Turnaround time can be considered a reliable indicator for
evaluation of laboratory staffing by identifying bottleneck
areas in any part of the test cycle. Turnaround time is
monitored to examine the functionality of the overall
service, including slide preparation, cytotechnologist screen-
ing, and pathologist sign-out. Turnaround time also relates
to customer satisfaction and may influence decisions about
where to refer gynecologic cytology work, especially
considering the competitive environment in the current
health care arena.17 In addition, as patients become more
knowledgeable about laboratory testing through targeted
marketing and other means, the demand for prompt
reporting increases, thus influencing the necessity to
monitor TAT.
Survey Results.—From the survey, a laboratory’s expec-
tations on Pap test TAT varied widely, from 1 to 7 or more
days, with a median Pap test TAT of 3 business days (Table
14). Laboratories reported that actual TAT was less than the
expected TAT, as shown in the percentile distributions in
Table 14. How laboratories define and measure TAT varied;
57.2% of respondents defined the starting point as the date/
time of accessioning the Pap test, while 24.1% used date/
time of specimen receipt, and 14.6% used date/time of
specimen collection. There was more universal agreement
on the definition of the ending point for TAT measurement,
as date/time report finalized (89.1%). Other definitions of
ending points included date/time results delivered to
physician (4.2%) and date/time case reviewed by technol-
ogist or pathologist (4.0%). The most common frequency of
TAT monitoring was monthly (46.6%), followed by daily
(20.4%) and quarterly (11.6%). The most common metric
used to measure TAT variance was percentile distribution
within a certain TAT (54.2%), followed by mean TAT
(32.4%) and percent of cases deviating from TAT expecta-
tion (15.5%) (Table 15).
Table 11. Are Abnormal Interpretations Confirmed
by Showing the Papanicolaou Test Slide
to Another Individual Before Final Sign-Out?
Frequency Percentage
Yes 33 49
No 33 49
Unsure 1 1
Total 67 100
If Yes, for Which of the Following Diagnoses?
(Check All That Apply)
ASCUS 9 22
ASC-H 11 28
LSIL 4 10
HSIL 12 30
AGC 12 30
Individual cases at the discretion
of the pathologist only
25 62
Abbreviations: AGC, atypical glandular cells of undetermined signif-
icance; ASC-H, atypical squamous cells, cannot exclude high-grade
squamous intraepithelial lesion; ASCUS, atypical squamous cells of
undetermined significance; HSIL, high-grade squamous intraepithelial
lesion; LSIL, low-grade squamous intraepithelial lesion.
Table 12. For Which Papanicolaou Test Findings
(Other Than Abnormal and Reactive) Do You Require
Pathologist Review?
Frequency Percentage
Benign endometrial cells 31 44
Unsatisfactory 41 59
Obscuring factors 10 14
Herpes 57 81
Individual cases at the discretion
of the pathologist only
16 23
Other glandular processes 25 36
Other 20 29
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Follow-up Questions Posted on Internet Site.—Five
additional questions were posted on the Web site to attempt
to supplement the written survey questions. The number of
responses on the Web site (76) was much lower than the
responses to the written survey. From the responses, 59% of
laboratories agreed that monitoring TAT is an effective
quality metric. Monitoring TAT was reported to be useful for
monitoring staffing needs in the laboratory, and as a metric
for customer service. Thirty-three percent of laboratories felt
that monitoring TAT is not an effective quality metric, with
several opinions stating that a faster TAT does not equate to
quality work. Eight percent of respondents were ‘‘unsure’’ if
Table 13. Consensus Good Laboratory Practice Statements:
Monitoring Concordance of Cytotechnologist and Pathologist Interpretations
Percentage
1a. Actively monitor rates at which a pathologist upgrades cytotechnologist interpretations before sign-out.
A. Agree, NILM to SILþ (negative to SIL or higher) 25.8
B. Agree, NILM to SILþ, also ASCUS to HSIL 25.8
C. Agree, A and B plus NILM to ASCUS 17.7
D. Agree, any upgrades to abnormal plus LSIL or ASC-H to HSIL 29.0
E. Do not monitor upgrades 1.6
1b. Revised statement: Actively monitor rates at which a pathologist upgrades
cytotechnologist interpretations before sign-out. Definition of upgrades should be determined by the
laboratory. Do you agree?
A. Yes 79.7
B. No 15.3
C. Other 3.4
D. Other 1.7
2. Actively monitor rates at which a pathologist downgrades cytotechnologist interpretations before sign-
out. Do you:
A. Agree, HSILþ or LSIL to NILM only 65.2
B. Agree, ASCUSþ (all abnormal) to NILM 10.1
C. Agree: all abnormal to NILM, and HSIL to ASC-H or LSIL 14.5
D. Do not monitor downgrades 10.1
3a. Show discrepancies of 2 degrees or more to a third person when possible. Do you:
A. Strongly agree 62.5
B. Agree with reservations 29.2
C. Disagree 8.3
3b. Revised statement: Laboratories should have policies about which categories of discrepancies should be
reviewed by a third individual before sign-out. Do you agree?
A. Yes 73.7
B. No 22.8
C. Other 3.5
4. Some cases benefit from review by a third person even if not upgraded/downgraded (squamous). Which
cases benefit from third-person review (squamous)?
A. ASC-H and greater 19.7
B. HSIL and greater 18.3
C. Squamous cell carcinoma only 22.5
D. Not necessary 39.4
5. Some cases benefit from review by a third person even if not upgraded/downgraded (glandular). Which
cases benefit from third-person review (glandular)?
A. Both atypical glandular cells and adenocarcinoma 55.4
B. Adenocarcinoma only 15.4
C. Not necessary 27.7
D. Other 1.5
6a. Some cases benefit from routine review by a second person even if CLIA does not require confirmation
by a pathologist. Which cases benefit from routine review by second person (cytotechnologist or
pathologist) even if not required by CLIA?
A. Herpes 4.0
B. Endometrial cells in women .40 y 0
C. Glandular cells in women post hysterectomy 2.7
D. B and C only (glandular processes) 16.2
E. All examples (A, B, C) 59.5
F. Not necessary routinely (only at the discretion of the screener) 17.6
6b. Revised statement: Laboratories should have policies as to which cases benefit from review by a second
person (cytotechnologist or pathologist), even if not required by CLIA. These may include:
–Unsatisfactory
–Endometrial cells in women .40 y
–Glandular cells in women post hysterectomy
–Herpes
Do you agree?
A. Yes 90.7
B. No 9.3
Abbreviations: ASC-H, atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion; ASCUS, atypical squamous cells of
undetermined significance; CLIA, Clinical Laboratory Improvement Amendments of 1988; HSIL, high-grade squamous intraepithelial lesion; LSIL,
low-grade squamous intraepithelial lesion; NILM, negative for intraepithelial lesion or malignancy; SIL, squamous intraepithelial lesion.
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monitoring TAT is an effective quality metric. There was
evidence of some misinformation for the requirement of
TAT monitoring, with 61% of respondents believing that
TAT monitoring was mandated, primarily by clinical
guidelines. Thirty-two percent of respondents report that
monitoring TAT negatively affects quality, including causing
undue pressure on cytotechnologists to meet screening
quotas. Of the 21% who report that monitoring TAT
positively affects quality, timely patient care and use as a
staffing monitor were given as examples. Forty-seven
percent of respondents were ‘‘unsure’’ if TAT constraints
negatively or positively affect quality, with many stating TAT
did not affect quality, or that TAT could have both positive
and negative effects.
Table 16 lists the good laboratory practice statements
generated from the written survey, Internet questions and
comments, and opinions of the authors, on monitoring Pap
test TAT. These statements were voted on at the consensus
conference. Most consensus conference participants agreed
that TAT should be monitored in gynecologic cytology
(Table 16, statement 1). Awareness of TAT should be a
consideration in the overall laboratory quality performance,
including addressing individual capabilities and limits.
However, the use of TAT monitoring should never
compromise the quality of the Pap test evaluation in any
phase of the cycle. Laboratory directors and managers
should be aware of the potential negative implications of
monitoring TAT. Thirty-two percent of respondents report
that monitoring TAT negatively affects quality, including
causing undue pressure on cytotechnologists to meet
screening quotas, possibly leading to increase in false-
negative rates and screening errors, and possibly leading to
increased ASCUS rates.
There was strong agreement among consensus confer-
ence participants that we should not attempt to establish a
universally acceptable TAT in gynecologic cytology (Table
16, statement 2). A specific TAT for Pap tests is not required
as certification criteria for laboratory inspections18 (CAP,
American Society of Cytopathology, CMS). There is no
evidence in the literature to support the establishment of a
TAT limit for Pap tests. The survey results showed a wide
range of laboratory TAT for Pap tests, ranging from 1 to 7 or
more days, with a median TAT of 3 business days.
Turnaround time is best used as an internal measure to
assess the workflow in gynecologic cytology rather than as a
benchmark for interlaboratory comparison.
Most consensus conference participants agreed that
individual laboratories should determine how to measure
or define TAT (Table 16, statement 3). The most common
measurement of TAT starts with date/time of accessioning
and ends with report sign-out. A minority of laboratories use
different definitions of TAT, and this should not pose a
problem, since the measurement is largely used for internal
assessments. There was strong agreement that individual
laboratories should determine the frequency of TAT mon-
itoring and the metric to determine TAT variance (Table 16,
statements 4 and 5). The needs for TAT monitoring may vary
Table 14. Turnaround Time (TAT) Expectations
Frequency Percentage
Laboratory’s expected Papanicolaou test TAT
in business days
1 33 7.7
2 90 21.0
3–4 122 28.4
5–6 123 28.7
.7 61 14.2
Laboratory’s median Papanicolaou test TAT
in business days
1 60 15.2
2 109 27.5
3–4 163 41.2
5–6 40 10.1
.7 24 6.1
Table 15. Turnaround Time (TAT) Monitoring
Frequency Percentage
Which metric is used to measure TAT variance? (N ¼ 491)a
Percentile distribution within a
certain TAT
266 54.2
Mean TAT 159 32.4
Percentage of cases deviating from
TAT expectation/standard
76 15.5
Median TAT 61 12.4
Average length of deviation from
TAT expectation/standard
39 7.9
Other 36 7.3
How frequently does the laboratory monitor Papanicolaou
test TAT?
Daily 104 20.4
Weekly 40 7.9
Monthly 237 46.6
Bimonthly 4 .8
Quarterly 59 11.6
Semiannually 13 2.6
Annually 23 4.5
Other 29 5.7
When does the clock start ticking for the TAT measurement?
Date/time accessioned 297 57.2
Date/time received for processing 125 24.1
Date/time collected 76 14.6
Other 8 1.5
Date/time ordered by provider 7 1.3
Date/time received for screening 5 1.0
Date/time results submitted for
reporting
1 .2
a Multiple responses were allowed.
Table 16. Consensus Good Laboratory Practice
Statements: Turnaround Time (TAT)
in Gynecologic Cytology
1. Turnaround time should be monitored in gynecologic
cytology. Do you agree?
A. Yes: 80.3%
B. No: 19.7%
2. We should not attempt to establish a universally acceptable
TAT in gynecologic cytology. Do you agree?
A. Yes: 90.1%
B. No: 9.9%
3. Individual laboratories should determine how to measure/
define TAT. Do you agree?
A. Yes: 74.3%
B. No: 25.7%
4. Individual laboratories should determine the frequency
of TAT monitoring. Do you agree?
A. Yes: 98.6%
B. No: 1.4%
5. Individual laboratories should determine the metric used to
measure TAT variance. Do you agree?
A. Yes: 91.3%
B. No: 8.7%
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by differences in individual laboratories, especially given
differences in laboratory information systems.
COMMENT
The good laboratory practice statements presented herein
have a range of consensus agreement or even disagreement,
reflecting differences in opinion and practice patterns of
consensus conference attendees. While there are many
strengths of this process, there are also shortcomings to the
methodology of this process. This process was not a
prospective study, but a survey of practice patterns and of
opinions from working group members and consensus
conference attendees. However, it would be difficult to
construct a prospective study of the numerous good practice
statements set forth in this survey, and many of the quality
monitors in this survey are mandated by regulations from
CLIA or accreditation criteria by CAP and other agencies.
While literature was reviewed and cited when possible, the
literature was not formally evaluated for strength of
evidence. Not infrequently, however, there was a dearth of
literature on certain quality topics, such as monitoring of
concordance between cytotechnologist and pathologist
interpretations of Pap tests before sign-out.
The working group authors and consensus conference
attendees were sensitive to the weaknesses and strengths of
this process. The good laboratory practice statements were
often crafted to not be proscriptive given the limitations of
this survey process and the vast differences among many
cytopathology laboratories. Indeed, the revisions to some of
the good laboratory practice statements noted above reflect
this struggle. The objective of these laboratory practice
statements are not to proscribe a regulated quality assurance
program, but rather to frame both areas of agreement and
disagreement so that cytopathology laboratories may choose
quality metrics, in addition to those mandated by regulations,
that may be suited to their particular practice. In cases of
metrics proscribed by CLIA regulations, the survey process
can highlight methods that may make the use of these metrics
more meaningful to the daily operation of the laboratory.
This report was supported in part from a contract (GS-10F-
0261K) funded by the Centers for Disease Control and Prevention/
Agency for Toxic Substances and Disease Registry. The authors
would like to acknowledge Barbara Blond, MBA, MT(ASCP) for her
many contributions to this project.
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